Newsletter
We send out weekly newsletters to our members about announcements, event information, and what YGCC is reading blog. You can find our past blog below.
Please subscribe to our newsletter now to keep track of the latest content!
What YGCC is Reading #585
UK Biotech Targets Office-Based Eye Gene Therapy
U.K. biotech Ikarovec has entered into a partnership with VectorBuilder to adapt its gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD) so it could be administered in a doctor’s office using a less invasive intravitreal injection. The collaboration relies on VectorBuilder’s AAV capsid technology to potentially shift treatment from hospital operating rooms to standard clinical settings. If successful, the agreement could be worth over $1 billion. Intermediate AMD currently has no approved treatments and often progresses to severe vision loss, making a one-time, more accessible therapy particularly appealing.
Questions:
-
How could moving gene therapies into doctors’ offices affect patient access and healthcare costs?
-
What risks or limitations might arise when simplifying how complex gene therapies are delivered?
Read more from Fierce Biotech.
Image adapted from Fierce Biotech.